Product Description
KN015,the active substance recombinant human Follicle Stimulating Hormone（FSH） Fc fusion protein, which belongs to the pharmaceutical class gonadotropins. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03192527)
Mechanisms of Action: FSH Inhibitor
Novel Mechanism: Yes
Modality: Fusion Protein
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Alphamab Jilin
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Infertility, Female|Infertility, Male
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| KNJR-2017-001 | P1 |
Unknown status |
Infertility, Female|Infertility, Male |
2019-03-01 |